Copperwynd Financial LLC Sells 2,460 Shares of Eli Lilly and Company (NYSE:LLY)

Copperwynd Financial LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 58.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,770 shares of the company's stock after selling 2,460 shares during the quarter. Copperwynd Financial LLC's holdings in Eli Lilly and Company were worth $1,462,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. WestEnd Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares during the period. Citizens National Bank Trust Department lifted its holdings in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $40,000. Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $43,000. Finally, O Brien Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded down $10.10 during trading on Monday, hitting $761.61. 1,996,304 shares of the stock were exchanged, compared to its average volume of 3,658,117. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a market capitalization of $721.80 billion, a price-to-earnings ratio of 61.97, a price-to-earnings-growth ratio of 1.12 and a beta of 0.40. The company's fifty day simple moving average is $767.03 and its 200-day simple moving average is $800.17. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.58 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is 48.82%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Morgan Stanley reiterated an "overweight" rating and issued a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Wall Street Zen lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Guggenheim raised their price objective on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Finally, The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.